Compugen vs Cellectis
CGEN and CLLS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGEN and CLLS compare
Compugen grew revenue faster over the last twelve months (161% versus 75.8% for Cellectis).
Compugen keeps more of each dollar of sales as profit, with a net margin of 48.6% compared with −92.7% at Cellectis.
Compugen scores higher on the StockData Score (12 against 3 for Cellectis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGEN | CLLS |
|---|---|---|
| Size and price | ||
| Share price | $2.10 | $1.18 |
| Change, 1 year | 25.0% | −67.7% |
| Change, 5 years | −55.4% | −86.8% |
| Beta (5Y) | 1.61 | 2.07 |
| Employees | 2 | 229 |
| StockData Score | ||
| Total score | 12 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 161% (better) | 75.8% |
| Revenue growth, 5Y average | 105% (better) | 7.4% |
| Profitability | ||
| Gross margin | 87.3% | 100% (better) |
| Operating margin | 43.1% (better) | −45.3% |
| Net margin | 48.6% (better) | −92.7% |
| FCF margin | 43.1% (better) | −57.2% |
| Return on equity | 50.9% (better) | −97.8% |
| Return on invested capital | 117% (better) | −122% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −0.6× |
| Current ratio | 5.72 | – |
| Piotroski F-score | 7 (better) | 3 |
| Ownership | ||
| Held by institutions | – | 9.4% |
| Held by insiders | 0.43% | 53.4% |
| Insider net buying, 12 months | −$126K | – |
| Short interest, % of float | 2.7% | – |
Go deeper
- CGEN stock overview
- CGEN income statement
- CGEN valuation and score
- CLLS stock overview
- CLLS income statement
- CLLS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.